Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of topical omiganan in usual type vulvar intraepithelial neoplasia
2015-002724-16Phase 2Completed
- Sponsor
- Biofrontera
- Start
- Sep 2015
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of omiganan in vulvar intraepithelial neoplasia (VIN), sponsored by Biofrontera. Primary endpoints: Efficacy endpoints and Pharmacodynamic endpoints. Started Sep 2015; status: completed.
02
Drugs
omiganan
03
Conditions
vulvar intraepithelial neoplasia (VIN)
Beyond the preview
Go deeper on 2015-002724-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002724-16.